October 5th, 2018
For the ALS patients in Canada,
we hope to deliver Japan-originated ALS treatment

Health Canada approves RADICAVATM (edaravone)
for the treatment of ALS
Mitsubishi Tanabe Pharma Corporation (MTPC) (Head Office: Osaka; President &Representative Director, CEO: Masayuki Mitsuka), announced today that Edaravone(US name: RADICAVA®; Japan names: RADICUT® BAG for I.V. Infusion 30mg) wasapproved by the Health Canada for an indication of amyotrophic lateral sclerosis(ALS), a rapidly progressive, neurodegenerative disease on October 3rd.
Granted under the Priority Review process, the Notice of Compliance (NOC)
authorization was based on a clinical trial which the primary endpoint was ameasurement utilizing the ALS Functional Rating Scale-Revised (ALSFRS-R), avalidated rating instrument for monitoring the progression of disability in patientswith ALS.
ALS is an idiopathic neurodegenerative disease in which motor neurons selectivelydegenerate and vanish. Muscle strength declines throughout the entire body,
including the limb, facial, and respiratory muscles, and muscular atrophy progress.
While the cause for the majority of cases is not well understood but may involve
genetic and environmental factors. It is one of the most well-known neuromusculardiseases, affecting approximately two in 100,000 people worldwide. According tothe ALS Society of Canada, an estimated 3,000 Canadians currently are living withALS, an incurable disease that affects the nerve cells in the brain and spin cord.
Promoting RADICAVATM in Canada will be handled by Mitsubishi Tanabe Pharma
Canada that was established by a sales subsidiary of Mitsubishi Tanabe Pharma onMarch 2018.
Mitsubishi Tanabe Pharma will strive to deliver edaravone to patients fighting against
ALS all over the world.

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119
Investor contacts: TEL:+81 6 6205 5110

1/2

<Reference>■ About edaravone
Edaravone is a free-radical scavenger that was discovered by Mitsubishi Tanabe
Pharma. It was approved by the Japanese Ministry of Health, Labor and Welfare inApril 2001 as a treatment agent for the acute stage of cerebral infarction. In Japan,
it is being marketed under the product name RADICUT®. Edaravone has the effectof scavenging free radicals that arise accompanying cerebral ischemia, controlling
the lipid peroxidation reaction, and protecting neurons in the region of the ischemia
and the surrounding region. Accordingly, it is thought that edaravone has the effectof scavenging free radicals, which increase in ALS, protecting motor neurons fromoxidative stress, and delaying the decline in muscle strength and the progress ofmuscular atrophy.

■ About Mitsubishi Tanabe Pharma Canada Ltd. (MTP-CA)
Based in Toronto, Ontario., MTP-CA was born in March 2018 as a subsidiary of
Mitsubishi Tanabe Pharma America Inc. that was established by Mitsubishi Tanabe
Pharma Corporation (MTPC) to commercialize approved pharmaceutical products inthe U.S. MTP-CA will promote RADICAVATM in the ALS new treatment option fornearly 20 years in Canada. MTP-CA is dedicated to delivering innovative productsthat address the unmet medical needs of patients in Canada.
https://www.mt-pharma-ca.com/en2/2